6,140
+3.89%
Close of 9 Nov 2026, in KRW
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Binex Co
Its shares trade on KOSDAQ under the ticker 053030.KQ. It has been listed since 7 August 2001. In the fiscal year to 31 December 2025, it reported revenue of ₩168.47bn and a net loss of ₩3.23bn. At that date it held total assets of ₩311.42bn and shareholders' equity of ₩187.30bn.
BINEX Co., Ltd. engages in the manufacture and sale of pharmaceuticals. The company is headquartered in Busan, Busan. The company went IPO on 2001-08-07. The Company’s products include digestive system agents, circulatory system agents, ulcer agents, antacids, anti-inflammatory agents, analgesics, gastrointestinal (GI) tract regulators and antispasmodics, antiemetic drugs, antihistamines, laxatives, antihypertensive and urinary agents, antibacterial and antibiotic agents, cough and cold remedies, anti-diabetic medicines, ophthalmic solutions, vitamins, nutrients, as well as ointment, creams and others. The company also manufactures bio medicines and raw materials. The firm distributes its products within domestic market and to overseas markets.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 7 Aug 2001
- Website
- bi-nex.com ↗
Leadership
Pay as last reported
- Mr. Myeong Ho JungChairman, since 2009
- Mr. Hyeok Jong LeePresident, Chief Executive Officer, Director, since 2015
- Mr. Myeong Cheol LeeVice President, Director, since 2020
- Mr. Jong Seong AhnVice President
- Mr. Hyeong Yil LeeVice President
- Mr. Jin Seop ChoAssistant Managing Director
- Mr. Jin Sun ChoiInternal Auditor
- Mr. Jae Pil GongAssistant Managing Director
- Mr. Su Yong JinAssistant Managing Director, since 2009
- Mr. Ji Yeong KimAssistant Managing Director
- Mr. Jin Su LeeAssistant Managing Director
- Mr. Bong Su SeoAssistant Managing Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Manufactures digestive system agents and circulatory system agents for domestic market
- Produces ulcer agents and antacids with strong domestic market presence
- Sells anti-inflammatory agents and analgesics in both domestic and overseas markets
Weaknesses
- Limited to domestic market for bio medicines and raw materials
- Relies on domestic market for ophthalmic solutions and vitamins
- Dependent on domestic market for antihistamines and laxatives
Opportunities
- Expanding into overseas markets for anti-diabetic medicines
- Growing demand for ophthalmic solutions in international markets
- Increasing global demand for bio medicines and raw materials
Threats
- Competition from domestic pharmaceutical companies
- Rising costs for raw materials in the Health Care sector
- Regulatory changes affecting pharmaceutical manufacturing in KR
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.